Tolucombi (Telmisartan / Hydrochlorothiazide)
Generic fixed-dose combination for high blood pressure (hypertension)
Tolucombi is a prescription generic combination medicine containing telmisartan 40 mg (an angiotensin II receptor blocker, or ARB) and hydrochlorothiazide 12.5 mg (a thiazide diuretic). It is used to treat essential high blood pressure (hypertension) in adults when telmisartan alone is not sufficient to reach target blood pressure. By combining two complementary mechanisms in a single tablet, Tolucombi simplifies therapy and helps reduce the long-term risk of stroke, myocardial infarction, heart failure, and kidney disease.
Quick Facts
Key Takeaways
- Tolucombi is a generic fixed-dose combination containing telmisartan 40 mg and hydrochlorothiazide 12.5 mg in a single once-daily tablet.
- It is prescribed for adults with essential hypertension whose blood pressure is not adequately controlled by telmisartan alone.
- Tolucombi must never be used during pregnancy, as it can cause serious harm to the unborn baby.
- Common side effects include dizziness, electrolyte changes (particularly low potassium), elevated uric acid, and altered blood lipids.
- Regular monitoring of blood pressure, kidney function, and serum electrolytes is important throughout treatment.
What Is Tolucombi and What Is It Used For?
Tolucombi belongs to a class of medicines known as combination antihypertensives. It contains two well-established active ingredients that have been used individually for decades in the treatment of high blood pressure. Telmisartan is an angiotensin II receptor blocker (ARB) that prevents the hormone angiotensin II from binding to its receptors in the walls of blood vessels. When angiotensin II is blocked, the blood vessels relax and widen, lowering the pressure inside them. Hydrochlorothiazide (HCTZ) is a thiazide diuretic that acts on the kidneys to promote the excretion of sodium and water. By reducing the volume of fluid circulating in the body, HCTZ further contributes to a lower blood pressure.
The rationale for combining these two agents in a single tablet is firmly established in clinical evidence. The 2023 European Society of Cardiology (ESC) and European Society of Hypertension (ESH) guidelines recommend initial combination therapy with two antihypertensive agents for most patients with hypertension, as monotherapy produces adequate blood pressure control in fewer than half of all patients. The pairing of an ARB with a thiazide diuretic is one of the preferred first-line combinations and is supported by major guidelines from the World Health Organization (WHO) and the UK National Institute for Health and Care Excellence (NICE).
High blood pressure, or hypertension, is one of the most important modifiable risk factors for cardiovascular disease worldwide. According to the WHO, an estimated 1.28 billion adults aged 30 to 79 years live with hypertension globally, and fewer than one in five have the condition adequately controlled. Uncontrolled hypertension substantially increases the long-term risk of stroke, heart attack, heart failure, chronic kidney disease, dementia, and premature death. Fixed-dose combinations such as Tolucombi simplify treatment by reducing the number of tablets a patient needs to take, which in turn improves adherence and long-term blood pressure control.
Tolucombi is specifically indicated for the treatment of essential hypertension in adults whose blood pressure is not adequately controlled by telmisartan alone. It is not a first-line treatment for newly diagnosed hypertension; rather, it is introduced when additional blood pressure lowering is required beyond what single-agent therapy can achieve. Because Tolucombi is a generic product, it provides the same therapeutic effect as the originator brand at a typically lower cost, broadening access to evidence-based combination therapy.
As a generic medicine, Tolucombi must meet the same quality, safety, and efficacy standards set by regulatory authorities such as the European Medicines Agency (EMA) and national regulators. Bioequivalence studies are required to demonstrate that the generic product delivers the active substances to the bloodstream at rates and extents equivalent to the reference product. Differences between Tolucombi and brand-name combinations such as MicardisPlus are limited to inactive ingredients, tablet shape, and packaging; the clinical effect in patients is expected to be the same.
What Should You Know Before Taking Tolucombi?
Before you are prescribed Tolucombi, your doctor will evaluate your medical history, concurrent medicines, and laboratory results to determine whether this combination is safe and appropriate for you. The considerations below summarise the most important contraindications, warnings, and precautions based on international regulatory assessments and clinical guidelines.
Contraindications
Tolucombi must not be used in the following situations. If any of these apply to you, inform your doctor immediately so that an alternative treatment can be selected:
- Hypersensitivity to telmisartan, hydrochlorothiazide, other sulfonamide-derived medicines, or any of the excipients (hydrochlorothiazide is chemically related to sulfonamides)
- Pregnancy at any stage, particularly during the second and third trimesters (see Pregnancy and Breastfeeding section below)
- Severe hepatic impairment, including cholestasis and biliary obstructive disorders
- Severe renal impairment (creatinine clearance below 30 mL/min) or anuria (absence of urine production)
- Refractory hypokalemia (persistently low potassium levels that do not respond to supplementation) or hypercalcemia
- Concomitant use with aliskiren in patients with diabetes mellitus or moderate-to-severe renal impairment (estimated glomerular filtration rate below 60 mL/min/1.73 m²)
Warnings and Precautions
Before starting Tolucombi, your doctor will need detailed information about all your medical conditions. Special caution is required in the following situations:
Kidney function: Both telmisartan and hydrochlorothiazide are partly eliminated through the kidneys, and both can affect renal perfusion. In patients with impaired renal function, more frequent monitoring of serum creatinine, potassium, and other electrolytes is recommended. Hydrochlorothiazide can reduce the effective circulating volume and exacerbate renal impairment in vulnerable patients, a risk further increased by concurrent use of non-steroidal anti-inflammatory drugs (NSAIDs), volume depletion, or dehydration.
Liver function: Telmisartan is predominantly eliminated via bile and should be used with caution in patients with mild-to-moderate hepatic impairment. In such patients, the daily dose of telmisartan should not exceed 40 mg, which corresponds to the strength of Tolucombi. Tolucombi is contraindicated in patients with severe hepatic disease or cholestatic disorders.
Electrolyte imbalances: Hydrochlorothiazide can cause clinically significant changes in serum electrolytes, including hypokalemia (low potassium), hyponatremia (low sodium), and hypomagnesemia (low magnesium). Although telmisartan can partially counteract potassium loss through its effect on aldosterone, regular blood tests to monitor electrolyte levels remain important, particularly during the first weeks of treatment and after any dose change. Patients at higher risk include the elderly, those on a low-sodium diet, and those with vomiting, diarrhoea, or concurrent use of other drugs that affect electrolytes.
Diabetes mellitus: Hydrochlorothiazide can impair glucose tolerance and may cause unmasking of latent diabetes or deterioration of existing glycaemic control. Patients with diabetes may require adjustment of their antidiabetic medicines, and blood glucose monitoring should be intensified after starting Tolucombi. In addition, the concurrent use of Tolucombi with aliskiren is contraindicated in patients with diabetes due to the risk of hyperkalemia, hypotension, and renal dysfunction from dual renin-angiotensin-aldosterone system (RAAS) blockade.
Gout and hyperuricemia: Hydrochlorothiazide reduces the excretion of uric acid by the kidneys, which can lead to elevated serum urate and precipitate acute gout attacks in predisposed individuals. Your doctor should monitor uric acid levels if you have a personal or family history of gout, and may consider alternative therapy if urate levels rise significantly.
Photosensitivity and skin cancer: Hydrochlorothiazide has been associated with photosensitivity reactions and, based on pharmacoepidemiological studies, an increased risk of non-melanoma skin cancer (particularly basal cell carcinoma and squamous cell carcinoma of the lip) with long-term cumulative exposure. Patients taking Tolucombi should limit exposure to direct sunlight and ultraviolet (UV) light, use broad-spectrum sunscreen, and report any suspicious skin lesions to their doctor for evaluation.
Acute angle-closure glaucoma: Hydrochlorothiazide has been rarely associated with an idiosyncratic reaction causing acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain, typically within hours to weeks of starting the medicine. If such symptoms occur, Tolucombi should be discontinued immediately and urgent ophthalmologic assessment sought.
In patients who are volume-depleted or salt-depleted, for example those on high-dose diuretic therapy, a salt-restricted diet, or those who have experienced prolonged vomiting or diarrhoea, symptomatic hypotension may occur after the first dose of Tolucombi. Volume depletion should be corrected before starting treatment, or Tolucombi should be initiated under close medical supervision. If dizziness or fainting occurs, lie down, raise your legs, and contact your doctor.
Pregnancy and Breastfeeding
Pregnancy: Tolucombi is strictly contraindicated during pregnancy. Medicines that act directly on the renin-angiotensin-aldosterone system (RAAS), such as telmisartan, can cause serious fetal toxicity including renal failure, oligohydramnios (reduced amniotic fluid), skull ossification defects, pulmonary hypoplasia, and fetal or neonatal death when used during the second and third trimesters. Even first-trimester exposure cannot be considered free of risk. Hydrochlorothiazide crosses the placenta and can cause fetal or neonatal jaundice, thrombocytopenia, and electrolyte disturbances. If pregnancy is detected while taking Tolucombi, the medicine should be discontinued immediately and an alternative antihypertensive that is compatible with pregnancy (such as methyldopa, labetalol, or nifedipine) should be started. Women of childbearing potential should use effective contraception while taking Tolucombi.
Breastfeeding: There are no adequate data on the excretion of telmisartan in human breast milk, and animal studies have shown excretion into milk. Hydrochlorothiazide is excreted into breast milk in small amounts and may suppress lactation. Because of the potential for serious adverse effects in the nursing infant, particularly newborns and premature infants, Tolucombi is not recommended during breastfeeding. Your doctor will help you decide whether to discontinue breastfeeding or to discontinue the medicine, taking into account the importance of the treatment for the mother.
Fertility: There is no clinical evidence that telmisartan or hydrochlorothiazide adversely affects fertility in men or women. However, if you are planning pregnancy, discuss alternative antihypertensive treatment with your doctor in advance.
How Does Tolucombi Interact with Other Drugs?
Drug interactions are an important consideration for any patient taking Tolucombi. Both telmisartan and hydrochlorothiazide can interact with a wide range of medicines, sometimes with clinically significant consequences. The tables below summarise the most important interactions. This is not an exhaustive list; always disclose every medicine, over-the-counter product, dietary supplement, and herbal remedy you take when starting or changing any prescription.
Major Interactions
| Interacting Drug | Effect | Clinical Recommendation |
|---|---|---|
| Lithium | Increased serum lithium concentrations with risk of lithium toxicity. Both telmisartan and HCTZ reduce renal lithium clearance. | Combination generally not recommended. If unavoidable, monitor lithium levels closely and adjust dose. |
| ACE inhibitors (e.g. ramipril, enalapril, lisinopril) | Dual RAAS blockade increases the risk of hyperkalemia, hypotension, syncope, and acute renal impairment. | Avoid combination in most patients. Contraindicated in patients with diabetic nephropathy. |
| Aliskiren | Triple RAAS blockade with increased risk of serious adverse cardiovascular and renal effects. | Contraindicated in patients with diabetes or renal impairment. Avoid in all other patients. |
| NSAIDs (e.g. ibuprofen, naproxen, diclofenac, high-dose aspirin) | May reduce the antihypertensive effect and increase the risk of acute kidney injury, particularly in the elderly or volume-depleted. | Use with caution. Ensure adequate hydration, monitor renal function and blood pressure, and use the lowest NSAID dose for the shortest duration. |
| Potassium supplements and potassium-sparing diuretics (e.g. spironolactone, amiloride) | Risk of hyperkalemia due to the potassium-sparing effect of telmisartan combined with external potassium loads. | Monitor serum potassium regularly if combination is clinically necessary. Discontinue potassium supplements if serum potassium rises. |
| Digoxin | Telmisartan may increase peak and trough digoxin concentrations. HCTZ-induced hypokalemia increases the risk of digoxin toxicity and arrhythmia. | Monitor digoxin levels and serum potassium. Consider dose adjustment of digoxin. |
Other Notable Interactions
| Interacting Drug | Effect | Clinical Recommendation |
|---|---|---|
| Other antihypertensive agents | Additive blood-pressure-lowering effect; increased risk of symptomatic hypotension, dizziness, or fainting. | Dose adjustments may be needed. Monitor blood pressure closely, especially at treatment initiation. |
| Corticosteroids and ACTH | May reduce the antihypertensive effect of hydrochlorothiazide and worsen potassium and fluid loss. | Monitor blood pressure, fluid balance, and electrolytes. |
| Insulin and oral antidiabetic medicines | HCTZ may impair glucose tolerance and reduce the effectiveness of antidiabetic therapy. | Monitor blood glucose more frequently when starting or changing Tolucombi. Dose adjustment of antidiabetic therapy may be needed. |
| Cholestyramine and colestipol | Reduce absorption of hydrochlorothiazide from the gastrointestinal tract. | Take Tolucombi at least 4 hours before or 4-6 hours after these bile acid sequestrants. |
| Alcohol, barbiturates, narcotics | May potentiate the blood-pressure-lowering effect and increase the risk of orthostatic hypotension. | Limit alcohol consumption. Rise slowly from sitting or lying positions. |
| Curare-type muscle relaxants | Enhanced response to non-depolarising muscle relaxants due to HCTZ-induced hypokalemia. | Inform anaesthetist before any planned surgery or general anaesthesia. |
What Is the Correct Dosage of Tolucombi?
Tolucombi 40/12.5 mg is the starting strength of the telmisartan/hydrochlorothiazide combination. It is typically prescribed after an initial treatment period with telmisartan 40 mg alone if blood pressure remains above target, or when a modest additional blood pressure reduction is needed. The dose should be taken at the same time each day to maintain steady plasma concentrations and stable blood pressure control.
Adults
Standard Dosing
The recommended dose is one Tolucombi 40/12.5 mg tablet once daily, taken at the same time each day, with or without food. The tablet should be swallowed whole with a glass of water and should not be chewed, crushed, or broken unless specifically advised by your doctor.
- Initiation: Tolucombi is usually started after a patient has been on telmisartan 40 mg monotherapy for at least 2 to 4 weeks without achieving the target blood pressure. It may also be initiated in patients for whom initial combination therapy is appropriate, typically those with stage 2 hypertension or high overall cardiovascular risk.
- Titration: If blood pressure remains above target after at least 4 weeks on Tolucombi 40/12.5 mg, the doctor may switch treatment to a higher-strength telmisartan/hydrochlorothiazide product (for example, 80/12.5 mg or 80/25 mg). The dose of Tolucombi itself cannot be increased because only the 40/12.5 mg strength is available.
- Onset and duration: The antihypertensive effect begins within a few hours of the first dose; the full blood-pressure-lowering effect typically develops over 4 to 8 weeks of continuous treatment.
Children and Adolescents
Paediatric Use
Tolucombi is not recommended for use in children and adolescents under 18 years of age. The safety and efficacy of the fixed-dose combination of telmisartan and hydrochlorothiazide have not been established in this age group. If pharmacological treatment of hypertension is required in children, alternative antihypertensive medicines with established paediatric dosing and safety data should be used under specialist supervision.
Elderly Patients
Dose Considerations in the Elderly
No routine dose adjustment is required in elderly patients. However, older individuals are generally more susceptible to electrolyte imbalances, dehydration, orthostatic hypotension, and impaired renal function. Treatment should therefore be initiated cautiously, with close blood pressure monitoring during dose titration, particularly in patients older than 75 years or those with multiple comorbidities. Routine monitoring of renal function and electrolytes is especially important in this age group, and the risk of falls should be considered when blood pressure is significantly lowered.
Renal and Hepatic Impairment
Dose in Renal and Hepatic Impairment
Tolucombi is contraindicated in severe renal impairment (creatinine clearance below 30 mL/min), in anuria, and in severe hepatic impairment or cholestatic disorders. In mild-to-moderate renal impairment, regular monitoring of renal function, serum potassium, and uric acid is recommended. In mild-to-moderate hepatic impairment, telmisartan should not exceed 40 mg daily, which corresponds to the strength contained in Tolucombi.
Missed Dose
If you forget to take a dose of Tolucombi, take it as soon as you remember on the same day. If it is close to the time of your next scheduled dose, skip the missed dose and take your next dose at the usual time. Do not take a double dose to make up for a missed one, as this may increase the risk of low blood pressure, dizziness, and electrolyte disturbances. If you frequently forget doses, consider setting a daily reminder or using a weekly pill organizer to help maintain a consistent dosing schedule.
Overdose
If you suspect an overdose of Tolucombi, seek emergency medical attention immediately. Symptoms of telmisartan overdose include marked hypotension, reflex tachycardia, and, less commonly, bradycardia, dizziness, and acute kidney injury. Hydrochlorothiazide overdose may cause severe electrolyte depletion (hypokalemia, hyponatremia, hypochloremia, metabolic alkalosis) and dehydration, with symptoms including nausea, vomiting, drowsiness, muscle cramps, and cardiac arrhythmias. Management is supportive and symptomatic and may include fluid resuscitation, correction of electrolyte imbalances, and monitoring of vital signs. Telmisartan is not removed by haemodialysis, while hydrochlorothiazide is removed to a limited extent.
What Are the Side Effects of Tolucombi?
The side-effect profile of Tolucombi reflects the combined effects of its two active ingredients. Clinical trials involving thousands of patients with the originator telmisartan/hydrochlorothiazide combination have provided a comprehensive picture of adverse reactions, and post-marketing surveillance over more than two decades has confirmed this profile. The frequency categories below follow the standard used by the European Medicines Agency (EMA) and the Medical Dictionary for Regulatory Activities (MedDRA).
Many of the biochemical changes associated with Tolucombi, particularly electrolyte shifts and metabolic changes caused by hydrochlorothiazide, may not cause noticeable symptoms but can still have clinical significance. This is why routine blood monitoring is recommended during long-term treatment, especially within the first weeks after starting therapy and after any dose change.
Common Side Effects
May affect up to 1 in 10 people
- Dizziness or lightheadedness
- Hypokalemia (low potassium in the blood)
- Hyperuricemia (elevated uric acid levels)
- Increased blood triglycerides
- Increased blood cholesterol
- Elevated blood glucose (hyperglycemia)
Uncommon Side Effects
May affect up to 1 in 100 people
- Hypotension, especially orthostatic (on standing)
- Hyponatremia (low sodium levels)
- Upper respiratory tract infections
- Urinary tract infections
- Back pain, muscle spasms, or myalgia
- Diarrhoea, nausea, dyspepsia, or dry mouth
- Fatigue or asthenia (weakness)
- Increased serum creatinine or blood urea nitrogen
- Skin rash, pruritus, or eczema
- Anxiety, depression, or insomnia
Rare Side Effects
May affect up to 1 in 1,000 people
- Angioedema (swelling of face, lips, tongue, or throat)
- Hepatic function abnormal or liver enzyme elevations
- Hyperkalemia (high potassium levels)
- Thrombocytopenia (low platelet count)
- Anaphylactic reactions
- Photosensitivity reactions (increased sensitivity to sunlight)
- Interstitial nephritis
- Visual disturbances and xanthopsia
- Erectile dysfunction
Very Rare / Post-Marketing Reports
May affect fewer than 1 in 10,000 people
- Acute angle-closure glaucoma
- Acute myopia (transient blurred vision)
- Aplastic anaemia or agranulocytosis
- Systemic lupus erythematosus exacerbation
- Acute pancreatitis
- Severe cutaneous adverse reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis
- Non-melanoma skin cancer with long-term cumulative exposure to hydrochlorothiazide
- Rhabdomyolysis
Contact your doctor or seek urgent medical attention if you experience any of the following while taking Tolucombi: swelling of the face, lips, tongue, or throat (possible angioedema); severe dizziness, fainting, or chest pain; signs of a severe allergic reaction such as widespread rash or difficulty breathing; unusual bleeding or bruising; severe or persistent muscle pain, weakness, or dark-coloured urine; sudden eye pain or loss of vision; significant change in the amount you urinate; or any new or changing skin lesion. These may indicate a serious side effect that requires prompt medical evaluation.
How Should You Store Tolucombi?
Proper storage of Tolucombi is essential to ensure that the active ingredients remain stable and effective throughout the stated shelf life. Telmisartan/hydrochlorothiazide tablets are sensitive to moisture, and hydrochlorothiazide in particular is hygroscopic. The tablets should therefore remain in their original blister packaging or container until immediately before use.
- Temperature: Store below 30°C (86°F). Do not freeze. Avoid exposure to extreme temperatures, such as in a car on a hot day or near a heat source.
- Moisture protection: Keep the tablets in the original blister or tightly closed container. Do not remove a tablet from the blister until just before it is taken. Avoid storage in bathrooms and kitchens, where humidity is higher.
- Light: Store in the original packaging to protect from direct sunlight.
- Children: Keep out of the sight and reach of children. A single tablet can cause significant hypotension and electrolyte disturbances in a small child.
- Expiry date: Do not use Tolucombi after the expiry date printed on the packaging. The expiry date refers to the last day of that month.
- Disposal: Do not dispose of unused medicines in household waste or wastewater. Return unused tablets to a pharmacy for safe destruction. This helps to protect the environment and prevents misuse.
What Does Tolucombi Contain?
Active Ingredients
Each Tolucombi 40/12.5 mg tablet contains:
- Telmisartan 40 mg: Telmisartan is a selective antagonist of the angiotensin II type 1 (AT1) receptor with high receptor affinity and a long terminal half-life of approximately 24 hours. This long half-life supports effective once-daily dosing and stable 24-hour blood pressure control, including the early-morning rise in blood pressure that is a known cardiovascular risk.
- Hydrochlorothiazide 12.5 mg: Hydrochlorothiazide is a benzothiadiazide (thiazide) diuretic that inhibits the sodium-chloride cotransporter in the distal convoluted tubule of the kidney. The result is increased urinary excretion of sodium, chloride, and water, with a modest reduction in circulating plasma volume. At this low dose, hydrochlorothiazide provides effective blood pressure lowering with a generally favourable metabolic profile.
Inactive Ingredients (Excipients)
The following excipients are commonly present in generic telmisartan/hydrochlorothiazide tablets. The exact composition of Tolucombi may vary slightly between manufacturers, and the most up-to-date list is always available in the product leaflet supplied with the medicine:
- Sodium hydroxide
- Povidone
- Meglumine
- Sorbitol (E420)
- Magnesium stearate
- Microcrystalline cellulose
- Lactose monohydrate
- Maize starch
- Iron oxide red (E172) (colouring agent)
Tolucombi may contain lactose and sorbitol. If your doctor has told you that you have an intolerance to some sugars, contact your doctor before taking this medicine. Patients with rare hereditary problems such as galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take Tolucombi. Always check the patient information leaflet for the full list of excipients relevant to your specific product.
Frequently Asked Questions About Tolucombi
Medical References
- European Society of Cardiology / European Society of Hypertension (2023). "2023 ESH Guidelines for the management of arterial hypertension." Journal of Hypertension. 41(12):1874-2071. Comprehensive European guidelines for hypertension management including combination therapy recommendations. Evidence level: 1A
- World Health Organization (2021). "Guideline for the pharmacological treatment of hypertension in adults." WHO Publication WHO evidence-based guideline for pharmacological treatment of hypertension in adults.
- European Medicines Agency (EMA). "Telmisartan/Hydrochlorothiazide - Summary of Product Characteristics." Official European regulatory product information for telmisartan/hydrochlorothiazide fixed-dose combinations.
- Sharpe M, et al. (2001). "Telmisartan: a review of its use in hypertension." Drugs. 61(10):1501-1529. Comprehensive review of telmisartan pharmacology, clinical efficacy, and tolerability.
- Yusuf S, et al. (2008). "Telmisartan, ramipril, or both in patients at high risk for vascular events." New England Journal of Medicine. 358(15):1547-1559. ONTARGET trial Landmark ONTARGET trial demonstrating telmisartan non-inferiority to ramipril in cardiovascular protection. Evidence level: 1A
- NICE (2022). "Hypertension in adults: diagnosis and management." NICE guideline [NG136]. UK clinical guideline for diagnosis and management of hypertension including combination therapy.
- British National Formulary (BNF). "Telmisartan with hydrochlorothiazide." Authoritative UK drug reference with dosing, interactions, and prescribing information.
- U.S. Food and Drug Administration (FDA). "Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)." FDA standards for therapeutic equivalence of generic medicines, including telmisartan/hydrochlorothiazide combinations.
Evidence grading: This article uses the GRADE framework (Grading of Recommendations Assessment, Development and Evaluation) for evidence-based medicine. Evidence level 1A represents the highest quality of evidence, based on systematic reviews of randomized controlled trials.
iMedic Editorial Standards
Peer Review Process
All medical content is reviewed by at least two licensed specialist physicians before publication.
Fact-Checking
All medical claims are verified against peer-reviewed sources and international guidelines.
Update Frequency
Content is reviewed and updated at least every 12 months or when new research emerges.
Corrections Policy
Any errors are corrected immediately with transparent changelog.
Medical Editorial Board: iMedic has an independent medical editorial board consisting of specialist physicians in cardiology, internal medicine, clinical pharmacology, and nephrology.